1-3 of 3
Lennart Friis-Hansen
Close
Sort by
Journal Articles

Impaired CD163-mediated hemoglobin-scavenging and severe toxic symptoms in patients treated with gemtuzumab ozogamicin

Brief Report
Maciej Bogdan Maniecki, Henrik Hasle, Lennart Friis-Hansen, Birgitte Lausen, Ove Juul Nielsen, Knud Bendix, Søren Kragh Moestrup, Holger Jon Møller
Journal: Blood
Blood (2008) 112 (4): 1510–1514.
https://doi.org/10.1182/blood-2007-09-114165
Published: 2008
Includes: Supplemental data
Journal Articles

The Predictive Value of Gene Expression Profiles for Acute Graft-Versus-Host Disease after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning for Hematological Malignancy.

Tania N. Masmas, MD, Lennart Friis-Hansen, M.D., Jens Vilstrup Johansen, M.S., Soren Lykke Petersen, M.D., Brian T. Kornblit, M.D., Ole Winther, M.S., Finn Cilius Nielsen, M.D., Lars Vindelov, M.D.
Journal: Blood
Blood (2007) 110 (11): 1079.
https://doi.org/10.1182/blood.V110.11.1079.1079
Published: 2007
Journal Articles

Impaired CD163 Mediated Hemoglobin-Scavenging and Hemolytic Crisis in Patients Treated with CD33 Targeted Chemotherapy (Gemtuzumab Ozogamicin, Mylotarg™).

Maciej B. Maniecki, MHSc, Henrik Hasle, MD, PHD, Lennart Friis-Hansen, MD, PHD, Birgitte Lausen, MD, PHD, Ove J. Nielsen, MD, PHD, Knud Bendix, MD, PHD, Soren K. Moestrup, MD, PHD, Holger J. Moller, MD, PHD
Journal: Blood
Blood (2007) 110 (11): 3684.
https://doi.org/10.1182/blood.V110.11.3684.3684
Published: 2007